Novartis AG Equity
Novartis AG (NVSEF) had Equity of $46.55 billion as of 2025-12-31, per its 20-F filed 2026-02-04.
Financial Statements › Notes
ifrs-full:Equity · last filed 2026-02-04
- 2025-12-31: Equity $46.55B.
- 2025-06-30: Equity $42.05B.
- 2025-03-31: Equity $38.45B.
- 2024-12-31: Equity $44.13B.
| Period end | Equity |
|---|---|
| 2025-12-31 | $46.55B 20-F · filed 2026-02-04 |
| 2025-06-30 | $42.05B 6-K · filed 2025-07-17 |
| 2025-03-31 | $38.45B 6-K · filed 2025-07-17 |
| 2024-12-31 | $44.13B 20-F · filed 2026-02-04 |
| 2024-06-30 | $41.90B 6-K · filed 2025-07-17 |
| 2024-03-31 | $39.76B 6-K · filed 2025-07-17 |
| 2023-12-31 | $46.75B 20-F · filed 2026-02-04 |
| 2023-06-30 | $51.93B 6-K · filed 2024-07-18 |
| 2023-03-31 | $52.14B 6-K · filed 2024-07-18 |
| 2022-12-31 | $59.42B 20-F · filed 2026-02-04 |
| 2022-06-30 | $63.01B 6-K · filed 2023-07-18 |
| 2022-03-31 | $61.70B 6-K · filed 2023-07-18 |
| 2021-12-31 | $67.82B 20-F · filed 2025-01-31 |
| 2021-06-30 | $54.13B 6-K · filed 2022-07-19 |
| 2021-03-31 | $50.59B 6-K · filed 2022-07-19 |
| 2020-12-31 | $56.67B 20-F/A · filed 2023-05-15 |
| 2020-06-30 | $53.88B 6-K · filed 2021-07-21 |
| 2020-03-31 | $50.98B 6-K · filed 2021-07-21 |
| 2019-12-31 | $55.55B 20-F · filed 2022-02-02 |
| 2019-06-30 | $51.50B 6-K · filed 2020-07-21 |
| 2019-03-31 | $47.31B 6-K · filed 2020-07-21 |
| 2018-12-31 | $78.69B 20-F · filed 2021-01-26 |
| 2018-06-30 | $76.90B 6-K · filed 2019-07-18 |
| 2018-03-31 | $71.21B 6-K · filed 2019-07-18 |
| 2018-01-01 | $74.29B 20-F · filed 2019-01-30 |
| 2017-12-31 | $74.23B 20-F · filed 2019-01-30 |
| 2017-06-30 | $69.98B 6-K · filed 2018-07-18 |
| 2017-03-31 | $67.65B 6-K · filed 2018-07-18 |
| 2016-12-31 | $74.89B 20-F · filed 2020-01-29 |
| 2015-12-31 | $77.12B 20-F · filed 2019-01-30 |
| 2014-12-31 | $70.84B 6-K · filed 2018-01-24 |